Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549

Hong-min DUAN; Nan CHEN; Yong-yan YANG; Yun-xia LI; Jin-xiang FENG; Hang LI; Xiu-wen HUANG; Dong-jin LV; Ming ZHANG; Yu-tao ZHAO

doi:10.12259/j.issn.2095-610X.S20210808

Volume 42 Issue 8

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(8): 40-46

Hong-min DUAN, Nan CHEN, Yong-yan YANG, Yun-xia LI, Jin-xiang FENG, Hang LI, Xiu-wen HUANG, Dong-jin LV, Ming ZHANG, Yu-tao ZHAO. Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549[J]. Journal of Kunming Medical University, 2021, 42(8): 40-46. doi: 10.12259/j.issn.2095-610X.S20210808

Citation:

Hong-min DUAN, Nan CHEN, Yong-yan YANG, Yun-xia LI, Jin-xiang FENG, Hang LI, Xiu-wen HUANG, Dong-jin LV, Ming ZHANG, Yu-tao ZHAO. Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549[J]. Journal of Kunming Medical University, 2021, 42(8): 40-46. doi: 10.12259/j.issn.2095-610X.S20210808

Citation:

Hong-min DUAN, Nan CHEN, Yong-yan YANG, Yun-xia LI, Jin-xiang FENG, Hang LI, Xiu-wen HUANG, Dong-jin LV, Ming ZHANG, Yu-tao ZHAO. Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549[J]. Journal of Kunming Medical University, 2021, 42(8): 40-46. doi: 10.12259/j.issn.2095-610X.S20210808

PDF( 1131 KB)

Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549

doi: 10.12259/j.issn.2095-610X.S20210808

1.
Dept. of Oncology，The 8th Affiliated Hospital of Dali University/The People’s Hospital of Lincang，Lincang Yunnan 677000
2.
Dept. of Thoracic Surgery，The 3rd Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital，Kunming Yunnan 650118
3.
Dept. of Geriatric Medicine，The 8th Affiliated Hospital of Dali University/The People’s Hospital of Lincang，Lincang Yunnan 677000
4.
Dept. of Medical Oncology，The 3rd Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital，Kunming Yunnan 650118
5.
Dept. of Radiotherapy Center，The 3rd Affiliated Hospital of Kunming Medical University/ Yunnan Cancer Hospital，Kunming Yunnan 650118，China

Received Date: 2021-06-28
Publish Date: 2021-08-25

Abstract

Abstract

Objective To investigate the effect and mechanism of anlotinib on radiosensitization of human lung adenocarcinoma cell line A549. Methods Human lung adenocarcinom cell line A549 was treated with anlotinib and/or radiotherapy, then divided in to four groups, control group （Ctrl）, Anlotinib treatment group （A）, irradiation group （RT） and anlotinib combined with irradiation group （A + RT）. CCK8 method was used to determine cell proliferation; the clone formation experiment was used to determine the inhibitory effect on cell growth; flow cytometry was used to determine cell cycle and apoptosis; immunofluorescence of γ-H2AX was used to determine DNA damage; expression of DNA-PKcs were detected by Western blot. Results Anlotinib inhibited proliferation and clonogenic survival following irradiation. The dose （Dq）, the average lethal dose （D0） and the survival score （SF2） in the anlotinib combined radiotherapy group was significantly lower than those in the radiotherapy group. Anlotinib decreased G2/M phase arrest and promoted the cells apoptosis induced by in irradiation. The confocal microscopy results showed the average number of γ-H2AX foci in the A+RT group was more than that in RT group. The protein levels of DNA-PKcs were higher in A + RT group than that in RT group. Conclusion Anlotinib enhances the radiosensitivity of A549 cells, which may be attributed to the delay DNA damage repair. It provides a rationale strategy by Anlotinib combined with irradiation for NSCLC.
- Anlotinib,
- Non-small cell lung cancer,
- Radiosensitization,
- DNA damage repair

FullText(HTML)

References(19)

References

[1]	李娜,邢书娟,黄国友,等. 抗肿瘤血管生成治疗的研究进展及应对策略[J]. 生命科学研究,2020,24(1):62-67.
[2]	Goedegebuure R S,De Klerk L K,Bass A J,et al. Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer?[J]. Frontiers in Immunology,2019,9(1):3107.
[3]	罗详冲,李高峰. 安罗替尼治疗肺癌的临床研究进展[J]. 中国肿瘤生物治疗杂志,2019,26(6):710-714.
[4]	Ruan X,Shi X,Dong Q,et al. Antitumor effects of anlotinib in thyroid cancer[J]. Endocrine-related cancer,2019,26(1):153-164. doi: 10.1530/ERC-17-0558
[5]	Yunus M,Jansson P J,Kovacevic Z,et al. Tumor-induced neoangiogenesis and receptor tyrosine kinases–mechanisms and strategies for acquired resistance[J]. Biochimica et Biophysica Acta(BBA)-General Subjects,2019,1863(7):1217-1225. doi: 10.1016/j.bbagen.2019.04.017
[6]	Bhanumathy K,Balagopal A,Vizeacoumar F S,et al. Protein tyrosine kinases:Their roles and their targeting in leukemia[J]. Cancers,2021,13(2):184-204. doi: 10.3390/cancers13020184
[7]	Karimian A,Mir S M,Parsian H,et al. Crosstalk between Phosphoinositide 3‐kinase/Akt signaling pathway with DNA damage response and oxidative stress in cancer[J]. Journal of Cellular Biochemistry,2019,120(6):10248-10272. doi: 10.1002/jcb.28309
[8]	Cuneo K C,Nyati M K,Ray D,et al. EGFR targeted therapies and radiation:Optimizing efficacy by appropriate drug scheduling and patient selection[J]. Pharmacology & Therapeutics,2015,154(5):67-77.
[9]	Bossi P,Platini F. Radiotherapy plus EGFR inhibitors:Synergistic modalities[J]. Cancers of the Head & Neck,2017,2(1):2.
[10]	倪莲芳,聂立功. 2017ASCO及WCLC晚期非鳞NSCLC抗血管生成治疗进展[J]. Chinese Journal of Lung Cancer,2018,21(5):425.
[11]	吴霞,冯国生. EGFR-TKI在局部晚期非小细胞肺癌中的应用[J]. 国际肿瘤学杂志,2016,43(4):312. doi: 10.3760/cma.j.issn.1673-422X.2016.04.020
[12]	徐萍,李红梅. 贝伐珠单抗在非小细胞肺癌中的应用进展[J]. Chinese Journal of Lung Cancer,2017,20(4):272.
[13]	Mok T S,Cheng Y,Zhou X,et al. Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations[J]. Drugs,2021,81(2):257-266. doi: 10.1007/s40265-020-01441-6
[14]	Xing L,Wu G,Wang L,et al. Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer:A multicenter,randomized,open-label,phase 2 trial[J]. International Journal of Radiation Oncology* Biology* Physics,2021,109(5):1349-1358. doi: 10.1016/j.ijrobp.2020.11.026
[15]	Ye H,Li Z,Liu K,et al. Anlotinib,a novel TKI,as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China:A systemic review and meta-analysis of its efficacy and safety[J]. Medicine,2021,100(23):e25709. doi: 10.1097/MD.0000000000025709
[16]	Toulany M. Targeting DNA double-strand break repair pathways to improve radiotherapy response[J]. Genes,2019,10(1):25. doi: 10.3390/genes10010025
[17]	Jachimowicz R D,Goergens J,Reinhardt H C. DNA double-strand break repair pathway choice-from basic biology to clinical exploitation[J]. Cell Cycle,2019,18(13):1423-1434. doi: 10.1080/15384101.2019.1618542
[18]	曹喆,庄亮,陈元. 吉非替尼对肺癌细胞株A549和H1975放射敏感度的影响及其机制[J]. 肿瘤防治研究,2014,41(4):324-330.
[19]	Tanaka T,Munshi A,Brooks C,et al. Gefitinib radiosensitizes non–small cell lung cancer cells by suppressing cellular DNA repair capacity[J]. Clinical Cancer Research,2008,14(4):1266-1273. doi: 10.1158/1078-0432.CCR-07-1606

Relative Articles(20)

Relative Articles

[1]	Shengqiang YANG, Ping WANG. Effect of Hsp90 Inhibitor Ganetespib Combined with Pemetrexed on Lung Adenocarcinoma Cells. Journal of Kunming Medical University, 2024, 45(7): 30-41. doi: 10.12259/j.issn.2095-610X.S20240705
[2]	Wangxun SHEN, Yinyu YANG, Canwei LI, Jinrong YANG, Sijing WU, Huajun ZHAO, Xiaoyu TUO. Expression and Clinical Significance of ROR1 in Different Histologic Types of Invasive Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20240509
[3]	Hongxiu YANG, Zhongshan ZHU. Effect of HPRT1 Gene Expression on Overall Survival of Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(8): 17-23. doi: 10.12259/j.issn.2095-610X.S20240803
[4]	Fei SONG, Jiayin CHE, Ming HUANG, Dan XU, Hongyang LI, Dingkun LI, Yingying XIANG. The Role of Radioactive Iodine-125 Particles in EMT and Clinical Treatment of Lung Adenocarcinoma. Journal of Kunming Medical University, 2023, 44(1): 140-143. doi: 10.12259/j.issn.2095-610X.S20230101
[5]	Shiqi MA, Yi DING, Min LI, Mengci WANG, Siyu ZHANG, Shumei FENG. LINC00341 Inhibits the Proliferation of Lung Adenocarcinoma Cells Through the MAPK Pathway. Journal of Kunming Medical University, 2023, 44(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20230403
[6]	Bangqing LIU, Jianfeng LI, Xiaohui LIU, Jinnan ZHANG, Jinping LIANG. MiR-196b Promotes Proliferation and Migration of Lung Adenocarcinoma by Targeting ERG. Journal of Kunming Medical University, 2023, 44(10): 83-91. doi: 10.12259/j.issn.2095-610X.S20231023
[7]	Zhongshan ZHU, Zhou YANG, Chengchuan JIANG, Xiaobing LI, Dou REN, Cheng HUANG, Weiwei ZHANG, Xiangjun LI, Shunli ZHAO. An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, 2022, 43(9): 70-76. doi: 10.12259/j.issn.2095-610X.S20220912
[8]	Huajun ZHAO, Guoqing PAN, Ying TANG, Zhiyuan WANG, Xiaowei ZHAO, Xiaoyu TUO. Expressions of ROR1 in Lung Adenocarcinoma and Its Relationship with Spread Through Air Apace. Journal of Kunming Medical University, 2022, 43(11): 22-29. doi: 10.12259/j.issn.2095-610X.S20221128
[9]	Maofang WU, Yongchun ZHOU, Jingjing CAI, Xin MO, Yinwei LI, Jiahui MAO. EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province. Journal of Kunming Medical University, 2022, 43(2): 60-66. doi: 10.12259/j.issn.2095-610X.S20220215
[10]	Ying-xia WANG, Qin HE, Guo-fang WANG, Xuan ZHANG. Expression and Significance of microRNA-21 and EGFR in Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2021, 42(8): 101-105. doi: 10.12259/j.issn.2095-610X.S20210818
[11]	Yan-fen MA, Jian HU, Ning ZHANG, Qian WU, Xiao-qin WANG. Changes and Abnormal Patterns of Coagulation Indicators in Patients with Lung Adenocarcinoma and Tuberculosis Pleural Effusion. Journal of Kunming Medical University, 2021, 42(10): 145-150. doi: 10.12259/j.issn.2095-610X.S20211021
[12]	Ma Guo Yu , Xiong Qing , Jiang Guo Qing , Yang Jia Tian , Mu Yun Zhen . . Journal of Kunming Medical University, 2020, 41(07): 30-37.
[13]	Wu Qi Yan , Bian Ge Yuan , Cheng Hui Jun, Li Jiao Xia , Wang Shu Ting , Huang Zhao Lue . . Journal of Kunming Medical University, 2020, 41(09): 32-37.
[14]	Zhang Zhi Xian , Gu Hou , Lin 劼, Lei Xue Fen , Jiang Li Feng , Li Nan , Lu Xin Yan , Yu Jia . . Journal of Kunming Medical University, 2019, 40(08): 97-101.
[15]	Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis. Journal of Kunming Medical University, 2018, 39(08): 47-50.
[16]	Wang Hua . . Journal of Kunming Medical University,
[17]	. Expression of GDNF,BDNF,NT3 and NT4 in Human Lung Adenocarcinoma Cell Lines A549. Journal of Kunming Medical University,
[18]	. Expression of GDNF and Changes of Cell Viability of Lung Adenocarcinoma Cell Lines A549. Journal of Kunming Medical University,
[19]	. The Comparison of Cell Viability between Xuanwei Lung Adenocarcinoma Cell Lines xwlc-05 and Cell Lines A549 in Vitro. Journal of Kunming Medical University,
[20]	. Expression of study of Nestin in Lung Adenocarcinoma Cell Line A549. Journal of Kunming Medical University,